BiotechTV - News

BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer

Jun 17, 2025
Ask episode
Chapters
Transcript
Episode notes